The EEF2K Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This polyclonal population, established through CRISPR/Cas9-mediated gene disruption, offers a loss-of-function model for the eukaryotic elongation factor 2 kinase (EEF2K) gene. The pool contains a heterogeneous mixture of edited cells, enabling robust functional studies without the need for single-cell cloning while avoiding clonal artifacts. Researchers can utilize this knockout model to interrogate EEF2K-dependent mechanisms in a physiologically relevant lung cancer background.
The host A-549 cell line was originally established from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits characteristics of type II alveolar epithelial cells. As a widely employed model in cancer biology, A-549 cells recapitulate key features of lung adenocarcinoma, including aberrant signaling networks, altered stress responses, and variable drug sensitivity. This cell line provides a clinically relevant platform for investigating tumor cell behavior, metastatic potential, and therapeutic resistance mechanisms.
EEF2K encodes a highly conserved calcium/calmodulin-dependent kinase that acts as a critical regulator of protein synthesis by phosphorylating eukaryotic elongation factor 2 (EEF2) at Thr56. This phosphorylation event reduces translation elongation and globally suppresses protein synthesis, thereby conserving cellular energy under adverse conditions such as nutrient deprivation or hypoxia. EEF2K activity is tightly controlled by upstream signals: it is activated by calcium/calmodulin binding and AMPK-mediated phosphorylation, while being inhibited through mTORC1- and PKA-dependent phosphorylation cascades. Insulin signaling and various stress stimuli also modulate EEF2K function. Downstream, EEF2K phosphorylates EEF2, which directly interacts with the ribosome to influence translational rates. Representative pathway components include calmodulin, EEF2K, EEF2, mTORC1, and AMPK, forming a signaling axis that connects environmental cues to translation control and cellular homeostasis. Additionally, EEF2K intersects with autophagy and calcium signaling pathways, expanding its regulatory network.
In the context of lung adenocarcinoma, EEF2K-mediated translational repression serves as an adaptive mechanism that promotes cell survival during metabolic stress, hypoxia, or exposure to chemotherapeutic agents. Consequently, EEF2K activity may contribute to tumor progression and the development of drug resistance in A-549 cells. Disrupting EEF2K in this model enables researchers to dissect the kinase’s role in cancer cell fitness, stress adaptation, and sensitivity to targeted therapies, particularly mTOR inhibitors. The A-549 knockout polyclonal population thus serves as a valuable tool to explore how EEF2K-dependent translational control influences lung adenocarcinoma biology.
This polyclonal knockout population is well-suited for a diverse array of experimental applications. Typical assays include Western blotting to monitor phospho-EEF2 levels and confirm loss of EEF2K protein expression, RT-qPCR to validate gene disruption, and puromycin incorporation assays to measure global translation rates. Functional studies can assess cell viability, apoptosis, migration, and invasion, while drug sensitivity testing (including mTOR inhibitors) and calcium flux assays further elucidate EEF2K’s role in signaling and resistance. The model supports investigations into translational control in cancer, stress-induced autophagy, drug resistance mechanisms, and lung adenocarcinoma pathophysiology. For further details or custom configurations, please contact Ascent Research.
